News from the HMI

New York, NY (December 16, 2022) – A New-York city-based Human Microbiology Institute presented “Bacterial DNA promotes tau and beta-amyloid aggregation and is suggested as a novel therapeutic target for Alzheimer’s disease” at the Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases.

New York, NY (October 20, 2022) – Human Microbiology Institute presented “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” at the CHEST 2021.

New York, NY (June 12, 2022) – Human Microbiology Institute presented their recent data “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” at the 44th European Cystic Fibrosis Conference.

Dr. George Tetz, MD, PhD, Human Microbiology Institute, NY, USA, is an invited speaker at Antibiotics Webinar | Antibiotics vs. Phage Therapy 10 May 2021

This webinar is focused on the comparison and interplay between antibiotics and phage therapy. George Tetz, will be giving a talk on the ole pf phages as possible human pathogens.  https://www.mdpi.com/journal/antibiotics/events

Abstract Title: Bacterial DNA Promotes Tau and Beta-amyloid Aggregation and Is Suggested as a Novel Therapeutic Target for Alzheimer’s Disease

Our abstract was accepted for an iPoster presentation at the #WorldMicrobeForum! Plan to see me online from June 20-24! Visit the website for details: https://bit.ly/3mLJcg1

New York, NY – July 22, 2020) – A New-York city-based start-up TGV-Dx was selected a winner in the special COVID-19 edition of the “Make Your Medical Device Pitch for Kids!” competition presented by FDA-sponsored National Capital Consortium for Pediatric Device Innovation. The competition focused on innovations in COVID-19-related pediatric medical devices that will improve children’s health care, with 16 finalists competing in a virtual pitch event for a share of $250,000 in total grant awards. TGV-Dx received a grant award as a result of their winning presentation

WASHINGTON, July 14, 2020 /PRNewswire/ — Sixteen finalists are announced in the “Make Your Medical Device Pitch for Kids!” special COVID-19 edition competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in COVID-19-related pediatric medical devices, the finalists will compete in a virtual pitch event held on July 20, 2020.

Interview to Forbes : SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2

In the interview to Forbes Dr. George Tetz highlights possible major scientific breakthroughs based on his article “SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2”

The full text is available at: https://www.forbes.com/sites/jvchamary/2020/04/17/prion-like-coronavirus/#6ea4b8df4680